February 01, 2015 6:09 PM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...

1750 Elm Street

Suite 103

Manchester, NH 03104

United States

Founded in 2009

8 Employees





Key Executives for Boston Therapeutics, Inc.

Age: 60
Total Annual Compensation: $71.7K
Chief Financial Officer
Age: 71
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 09:15 AM

Boston Therapeutics, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 09:15 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: David Platt, Founder, Chairman, Chief Executive Officer and Treasurer.

Boston Therapeutics, Inc. Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss

Boston Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug Application for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015. This study is being designed as a randomized, placebo-controlled, double-blind, international multicenter study with two treatment arms. It will evaluate the effect of BTI-320 in addition to current treatment with metformin, Dipeptidyl peptidase-4 inhibitors (DPP-4), sulfonylureas and/or long-acting insulin analog on glucose control in patients with Type 2 diabetes. The primary efficacy endpoint of the trial is the mean change in HbA1c levels from baseline at 24 weeks. The study will be conducted at number of international centers located in the U.S., Europe, Asia and Australia. Up to 360 subjects will be enrolled and treated in the study.

Boston Therapeutics and Sugardown Company Ltd. Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia

Boston Therapeutics, Inc. and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion. In connection with this development, Boston Therapeutics received a purchase order from Sugardown Company Ltd. for 60,000 units to be tentatively shipped by the end of the first quarter of 2015. Under the terms of the original agreement, SugarDown Company Ltd. can market sugardown(R) in China, Hong Kong and Macau. The new agreement expands the marketing initiative to Korea, Taiwan, Singapore, Thailand, Malaysia, Vietnam, Philippines, Myanmar, Indonesia, Laos, Brunei and Cambodia. Advance has already been granted marketing approval in Singapore, Macau, and Korea along with Hong Kong. The main China registration will enter the clinical testing phase early in 2015 with a projected approval tentatively set for later in the year.

Similar Private Companies By Industry

Company Name Region
Pharmaceutical Holdings Corporation United States
Berkeley Bio-Organic Research Laboratories United States
Solaris Therapeutics, Inc. United States
Pipejoin Technologies, Inc. United States
Zoetis Products LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boston Therapeutics, Inc., please visit www.bostonti.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.